Why Is Fluconazole a Hazardous Drug Under NIOSH

Fluconazole is classified as a hazardous drug because repeated occupational exposure can harm fetal development and reproduction. The National Institute for Occupational Safety and Health (NIOSH) puts it on the hazardous drug list to protect the pharmacy technicians, nurses, and other workers who handle it day after day, not to warn patients away from a prescribed course. A patient taking fluconazole for a yeast infection and a technician counting fluconazole tablets forty hours a week are in very different situations, and the label is aimed at the second one.

The Specific Reason: Fetal Harm at High Doses

Fluconazole’s hazardous status rests on documented reproductive and developmental toxicity. Case reports have described a pattern of skeletal and craniofacial birth defects in infants whose mothers took high-dose fluconazole, 400 to 800 mg per day, throughout most or all of the first trimester to treat serious systemic fungal infections.¹

On the strength of those reports, the FDA moved fluconazole from pregnancy Category C to Category D for every indication except a single 150 mg dose for vaginal candidiasis. Category D means there is positive evidence of human fetal risk, though the drug may still be justified when an infection is life-threatening. The single 150 mg dose stayed in Category C.¹

Large epidemiological studies of nearly 9,000 pregnant patients who took a single 150 mg dose found no increased rate of congenital malformations or miscarriage compared to unexposed pregnancies.² The concern behind the hazardous classification is the high-dose, long-term exposure pattern. For NIOSH purposes, it does not matter how common that pattern is in clinical practice; the existence of documented developmental toxicity is enough.

How NIOSH Decides a Drug Is Hazardous

NIOSH maintains a list of drugs that can cause health problems in the people who prepare, transport, and administer them. A drug qualifies if it shows any one of these properties in humans, animal studies, or laboratory testing: carcinogenicity, genotoxicity, developmental toxicity, reproductive toxicity, organ toxicity at low doses, or structural similarity to a drug already flagged for any of those reasons.³

Meeting one criterion is enough. Fluconazole meets two, both in the reproductive family. The classification is purely about occupational risk to workers, not about whether the medication works or whether patients should take it.

Where Fluconazole Sits on the List

Not every hazardous drug carries the same handling profile, and NIOSH sorts the list into two tables. Table 1 holds the drugs with the most severe workplace risk: those with manufacturer’s special handling instructions, known or probable human carcinogens, and cytotoxic agents. Many chemotherapy drugs live here.

Fluconazole sits in Table 2, flagged as a developmental and reproductive hazard only.³ That placement matters. Table 2 drugs do not carry the same mandatory handling intensity as Table 1, and USP General Chapter 800 gives facilities room to tailor protections to the actual exposure risk.

What This Means for Workers Who Handle It

The exposure pattern the label targets is chronic and low-level: skin contact with contaminated vials, counting trays, or work surfaces, and inhalation of drug dust during compounding. A pharmacy technician might handle fluconazole and dozens of other hazardous drugs across a full career, and NIOSH is trying to protect that person, not the patient taking a five-day course.³

The exposure question sharpens for workers who are pregnant, trying to conceive, or breastfeeding. Because fluconazole’s hazardous classification is driven entirely by reproductive and developmental toxicity, these workers face the most direct threat from unprotected handling. Facilities are expected to identify such workers and give them the option to avoid hazardous drug duties or use the highest level of protection available.

Under OSHA’s Hazard Communication Standard, employers must train every worker who may encounter hazardous drugs, both at initial assignment and whenever a new hazardous chemical enters the work area. Training covers how to detect the presence or release of a hazardous drug, the specific health risks, the protective measures, and how to read safety data sheets and labels.⁴

What It Means for a Pharmacy Dispensing Tablets

A common misunderstanding is that any drug on the NIOSH list demands the full compounding-suite treatment. USP General Chapter 800 draws a sharper line than that. Compounding hazardous drugs, whether crushing tablets for a suspension or preparing an IV solution, does require containment: a ventilated primary engineering control inside a negative-pressure room, gowns tested for drug permeation, two pairs of chemotherapy-tested gloves, and closed-system transfer devices when the dosage form allows.⁵

Counting sealed tablets is not compounding. For intact final dosage forms that do not require any manipulation beyond counting or repackaging, a facility does not need those engineering controls as long as no visible dust or leakage is present.⁵ That is the provision keeping community pharmacies from needing a hazardous drug suite to dispense fluconazole tablets.

USP 800 also allows facilities to perform a written assessment of risk for hazardous drugs that are not antineoplastic and do not require manipulation. A documented assessment lets a facility adopt containment strategies matched to the actual exposure, rather than defaulting to the full suite of controls. Skip the assessment, and the default applies: handle every hazardous drug with the full containment strategy.⁶

The strictest personal protective equipment mandates under USP 800 target injectable antineoplastic drugs. Fluconazole is not antineoplastic. For non-antineoplastic hazardous drugs, the chapter directs each facility to define appropriate PPE in its standard operating procedures based on its safety plan and any completed assessment of risk. Chemotherapy gloves are still recommended for handling any hazardous drug, and most facilities require at least single chemotherapy gloves and a gown when administering IV fluconazole, but the double-gloving and closed-system transfer device requirements that apply to chemotherapy do not automatically extend to fluconazole.⁷

What It Does Not Mean for the Patient

If you were prescribed fluconazole and saw the “hazardous drug” language on your pharmacy paperwork, that label is not a warning about your treatment. It is a workplace flag for the people who handle the medication in bulk. A patient takes a defined course under a doctor’s supervision, with the infection weighed against the known risks; a technician handles the same drug repeatedly for years. Those are different exposure profiles, and the classification exists to address the second one. If you are pregnant or may become pregnant and fluconazole has been prescribed, that is a conversation for your prescribing clinician, informed by the same FDA pregnancy category information described above.

1
U.S. Food and Drug Administration. FDA Drug Safety Communication: Use of Long-Term, High-Dose Diflucan (Fluconazole) During Pregnancy May Be Associated With Birth Defects in Infants
2
National Center for Biotechnology Information (NCBI). Fluconazole Exposure During Pregnancy
3
National Institute for Occupational Safety and Health (NIOSH). NIOSH List of Hazardous Drugs in Healthcare Settings, 2024
4
Occupational Safety and Health Administration. Hazard Communication
5
USP-NF. General Chapter 800 Hazardous Drugs – Handling in Healthcare Settings Revision Bulletin
6
USP – US Pharmacopeia (USP). Hazardous Drugs – Handling in Healthcare Settings
7
USP-NF. General Chapter 800 Hazardous Drugs – Handling in Healthcare Settings